Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status.

Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status.

Publication date: Sep 24, 2018

Personalised medicine targeted to specific biomarkers such as BRAF and c-Kit has radically improved the success of melanoma therapy. More recently, further advances have been made using therapies targeting the immune response. In particular, therapies targeting the PD-1/PD-L1 or CTLA-4 axes alone or in combination have shown more sustained responses in 30-60% of patients. However, these therapies are associated with considerable toxicities and useful biomarkers to predict responders and non-responders are slow to emerge. Here we developed a reliable melanoma circulating tumor cell (CTC) detection method with PD-L1 evaluation on CTCs. A set of melanoma cell surface markers was tested as candidates for targeted melanoma CTC isolation and a melanoma specific immunostaining-based CTC identification protocol combined with PD-L1 detection was established. In vitro testing of the effect of exposure to blood cells on melanoma cell PD-L1 expression was undertaken. Immunomagnetic targeting isolated melanoma CTCs in up to 87.5% of stage IV melanoma patient blood samples and 3 8.6% of these had some PD-L1 expressing CTCs. Our in vitro data demonstrate PD-L1 induction on melanoma cells in the blood.This study established a robust, reliable method to isolate melanoma CTCs and detect expression of PD-L1 on these cells.

Open Access PDF

Po, J.W., Ma, Y., Balakrishna, B., Brungs, D., Azimi, F., de Souza, P., and Becker, T.M. Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status. 21639. 2018 PLoS One (14):2.



Please signin to view all article content and metadata.


Leave a Comment